RadioGel® retweeted
"One of the really wonderful and important things in his case is that the possibility of treating him with a single treatment also allowed us to avoid increasing the risk of complications related to his other medical conditions. " - Dr. Sanchez, Oncologist at NorthStarVETS $RDGL
RadioGel® retweeted
Meet Major! 1 year after treatment and no signs of recurrence! His case study titled Adjuvant Interstitial Yttrium-90 Hydrogel (IsoPet®) Following Limb-Sparing Marginal Excision of Multifocal Distal Pelvic-Limb Neoplasia in a Dog is available on our websites!
RadioGel® retweeted
Exciting news for IsoPet! A newly published, peer-reviewed case report documents a dog treated with IsoPet® after limb-sparing cancer surgery, with no detectable local recurrence at 120 days. Read more on our website! $RDGL
isopet.com/research-papers/
RadioGel® retweeted
Vivos Inc. announces 4 new veterinary clinics advancing toward @IsoPetForCancer certification across the U.S.! Growing clinical adoption, expanding treatment capacity, and building a scalable network for recurring revenue growth. $RDGL
globenewswire.com/news-relea…
RadioGel® retweeted
Vivos Inc. continues to build momentum with growing @IsoPetForCancer adoption, expanding clinic partnerships, and continued progress for @RadioGel human clinical trials. Read our Business Update for the latest developments! $RDGL
vivosinc.com/vivos-inc-provi…
RadioGel® retweeted
When your pet faces cancer, understanding treatment options matters. Contact us through our website for our help to connect you to one of our IsoPet® certified veterinary clinics across America. We’re here to answer your questions! $RDGL
🤖 Made with AI
RadioGel® retweeted
When a pet undergoes cancer surgery, there can be concerns about cancer cells remaining behind. IsoPet®’s New Postoperative Therapy is designed to target these areas with localized radiation, offering veterinarians and parents another treatment option.$RDGL
🤖 Made with AI
RadioGel® retweeted
Please see our website for the latest Business Update on our progress with the Mayo Clinic Human Cancer Trials for @radiogel and more answers to your questions on our Investors Q&A page! $RDGL
vivosinc.com/vivos-inc-busin…
RadioGel® retweeted
EANM’26 brings together leading experts from around the world in nuclear medicine, molecular imaging, and theranostics. Vivos was in attendance, building key relationships to support the expansion of @RadioGel and @IsoPetForCancer into global markets. $RDGL
RadioGel® retweeted
Exciting growth for @IsoPetForCancer Organic search traffic surged 114% in 2026, with stronger Google/AI search visibility, record pet owner inquiries, and more animals receiving treatment. Read our latest Business Update here $RDGL
vivosinc.com/isopet-com-repo…
RadioGel® retweeted
Meet Percy who received IsoPet Precision Radionuclide Therapy at Sun City Veterinary Surgery Center in El Paso, TX. His remarkable progress shows the promise of targeted cancer therapy and brings hope to pets and the families who love them. $RDGL
RadioGel® retweeted
We are excited to be at ACVS to see Dr. Kevin Drygas presenting his clinical research on Post Operative Precision Radionuclide Brachytherapy! His research has paved the way for IsoPet as an option for pets with cancer who cannot pursue traditional radiation therapy. $RDGL
RadioGel® retweeted
Exciting news from @VivosIncUSA Team IsoPet - Animal Cancer Division is gearing up to showcase at ACVS in Charlotte, NC this week. We're thrilled to present Precision Radionuclide Therapy as an innovative solution for treating cancer in both small and large animals. $RDGL
RadioGel® retweeted
Vivos has posted a Business Update highlighting progress from peer-reviewed publication and U.S. clinical readiness to international expansion and a stronger path toward commercialization. Visit our website for details. $RDGL
vivosinc.com/september-2026-…
RadioGel® retweeted
Vivos is building momentum! Our Business Strategy Advisory Board aligned on key actions to complete our current development phase and prepare for our next major business phase. Stay tuned for our September business update later today highlighting progress! $RDGL
RadioGel® retweeted
Vivos is pleased to provide a business update on the continued advancement of its U.S. first-in-human feasibility study of RadioGel®, as the Mayo Clinic clinical process progresses toward IRB submission. $RDGL
vivosinc.com/radiogel-irb-up…
RadioGel® retweeted
Francis’ story truly touches our hearts. 💙 Diagnosed at 11yrs and given just 6 months to live, his mom refused to give up. They traveled to Johns Hopkins for treatment—and today, Francis is celebrating his 16th year. Every extra moment matters. 🐾 $RDGL
RadioGel® retweeted
We’re pleased to share our new dedicated Investor Relations FAQ page, featuring answers to the most common questions we receive from our valued followers. Visit VivosInc.com for the latest company information and updates. $RDGL
vivosinc.com/investor-relati…
RadioGel® retweeted
A press release was issued for the peer-reviewed publication for PrecisionGel™ in the Journal of Drug Delivery Science and Technology. PrecisionGel™ is the polymer carrier component of both @IsoPetForCancer and @RadioGel $RDGL
globenewswire.com/news-relea…
RadioGel® retweeted
A major milestone for Vivos! @IsoPetForCancer is officially shipping from our APEL facility in Richland, WA! In-house production strengthens supply, quality and scalability while positioning Vivos for continued growth in the U.S. and worldwide. $RDGL













